These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


147 related items for PubMed ID: 16391181

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
    Mubashar M, Harrington KJ, Chaudhary KS, Lalani el-N, Stamp GW, Sinnett D, Glass DM, Peters AM.
    J Nucl Med; 2002 Apr; 43(4):519-25. PubMed ID: 11937596
    [Abstract] [Full Text] [Related]

  • 26. The role of 99mTc-depreotide in the management of neuroendocrine tumours.
    Shah T, Kulakiene I, Quigley AM, Warbey VS, Srirajaskanthan R, Toumpanakis C, Hochhauser D, Buscombe J, Caplin ME.
    Nucl Med Commun; 2008 May; 29(5):436-40. PubMed ID: 18391727
    [Abstract] [Full Text] [Related]

  • 27. [Fusion of pulmonary scintigraphy with Tc99m-depreotide imaging with CT scan in recognizing solitary pulmonary nodule].
    Szaluś N, Chciałowski A, From S, Zagrodzka M, Pietrzykowski J, Dziuk E.
    Pol Merkur Lekarski; 2008 Oct; 25(148):330-4. PubMed ID: 19145931
    [Abstract] [Full Text] [Related]

  • 28. [Assessment of autoimmune disease activity in endocrine orbitopathy: comparison of SPECT using 99m-Tc-DTPA or 99m-Tc-depreotide and MRI scores].
    Galuska L, Nagy E, Szúcs-Farkas Z, Szabados L, Garai I, Szabó J, Varga J, Leövey A.
    Orv Hetil; 2003 Oct 12; 144(41):2017-22. PubMed ID: 14631894
    [Abstract] [Full Text] [Related]

  • 29. Depreotide scanning in sarcoidosis: a pilot study.
    Shorr AF, Helman DL, Lettieri CJ, Montilla JL, Bridwell RS.
    Chest; 2004 Oct 12; 126(4):1337-43. PubMed ID: 15486401
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Evaluation of early treatment response and predicting the need for colectomy in active ulcerative colitis with 99mTc-HMPAO white blood cell scintigraphy.
    Bennink RJ, Peeters M, Rutgeerts P, Mortelmans L.
    J Nucl Med; 2004 Oct 12; 45(10):1698-704. PubMed ID: 15471836
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography.
    Mezi S, Primi F, Capoccetti F, Scopinaro F, Modesti M, Schillaci O.
    Int J Oncol; 2003 Jun 12; 22(6):1233-40. PubMed ID: 12738988
    [Abstract] [Full Text] [Related]

  • 35. Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging.
    Wang F, Wang Z, Yao W, Xie H, Xu J, Tian L.
    J Nucl Med; 2007 Sep 12; 48(9):1442-8. PubMed ID: 17704242
    [Abstract] [Full Text] [Related]

  • 36. 99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphoma.
    Bushnell DL, Menda Y, Madsen MT, Link BK, Kahn D, Truhlar SM, Juweid M, Shannon M, Murguia JS.
    Nucl Med Commun; 2004 Aug 12; 25(8):839-43. PubMed ID: 15266180
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The usefulness of 99mTc-tetrofosmin SPECT in the detection of lung metastases from extrapulmonary primary tumors.
    Spanu A, Solinas ME, Farris A, Arru A, Chessa F, Madeddu G, Falchi A, Madeddu G.
    Radiol Med; 2004 Aug 12; 107(1-2):113-27. PubMed ID: 15031703
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 8.